Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Multitrace -4

×

Overview

What is Multitrace -4?

MULTITRACE® - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)

Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg and Chromium 10 mcg. Each mL contains: Zinc Sulfate Heptahydrate 22 mg (equivalent to 5 mg Zinc); Cupric Sulfate Pentahydrate 3.93 mg (equivalent to 1 mg Copper); Manganese Sulfate Monohydrate 1.54 mg (equivalent to 0.5 mg Manganese); Chromic Chloride Hexahydrate 51.3 mcg (equivalent to 10 mcg Chromium); and Water for Injection, q.s. pH of the solution may have been adjusted with Sulfuric Acid and/or Sodium Hydroxide. The 10 mL Multiple Dose Vial contains 0.9% Benzyl Alcohol as an antimicrobial preservative.



What does Multitrace -4 look like?



What are the available doses of Multitrace -4?

Sorry No records found.

What should I talk to my health care provider before I take Multitrace -4?

Sorry No records found

How should I use Multitrace -4?

This formulation is indicated for use as a supplement to intravenous solutions given for TPN. Administration of the solution in TPN solutions helps to maintain plasma levels of zinc, copper, manganese, and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms.

Each mL of the solution provides Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg. The suggested dosage ranges for the four trace elements are:

ZINC

For the metabolically stable adult receiving TPN, the suggested intravenous dosage level is 2.5 to 4 mg zinc/day. An additional 2 mg zinc/day is suggested for acute catabolic states. For the stable adult with fluid loss from the small bowel, an additional 12.2 mg zinc/liter of small bowel fluid lost, or an additional 17.1 mg zinc/kg of stool or ileostomy output is recommended. Frequent monitoring of zinc blood levels is suggested for patients receiving more than the usual maintenance dosage level of zinc. Normal plasma levels for zinc vary from approximately 88 to 112 mcg/100 mL.

For full term infants and children up to 5 years of age, 100 mcg zinc/kg/day is recommended. For premature infants (birth weight less than 1500 g) up to 3 kg in body weight, 300 mcg zinc/kg/day is suggested.

COPPER

For the metabolically stable adult receiving TPN, the suggested additive dosage level is 0.5 to 1.5 mg copper/day. For pediatric patients, the suggested additive dosage level is 20 mcg copper/kg/day. The normal plasma range for copper is approximately 80 to 160 mcg/100 mL.

MANGANESE

For the metabolically stable adult receiving TPN, the suggested additive dosage level for manganese is 0.15 to 0.8 mg/day. For pediatric patients, a dosage level of 2 to 10 mcg manganese/kg/day is recommended.

CHROMIUM

For the metabolically stable adult receiving TPN, the suggested additive dosage level is 10 to 15 mcg chromium/day. The metabolically stable adult with intestinal fluid loss may require 20 mcg chromium/day with frequent monitoring of blood levels as a guideline for subsequent administration. For pediatric patients, the suggested additive dosage level is 0.14 to 0.20 mcg/kg/day.

Periodic monitoring of plasma levels of Zinc, Copper, Manganese, and Chromium is suggested as a guideline for administration.

Aseptic addition of the solution to the TPN solution under a laminar flow hood is recommended. The trace elements present in the solution are physically compatible with the electrolytes and vitamins usually present in the amino acid/dextrose solution used for TPN.

Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit.

Store at 20to 25C (68to 77F); excursions permitted to 15to 30C (59to 86F) (See USP Controlled Room Temperature).


What interacts with Multitrace -4?

Sorry No Records found


What are the warnings of Multitrace -4?

Sorry No Records found


What are the precautions of Multitrace -4?

Sorry No Records found


What are the side effects of Multitrace -4?

Sorry No records found


What should I look out for while using Multitrace -4?

MULTITRACE

- 4 CONCENTRATE

Copper and Manganese are eliminated via the bile. In patients with severe liver dysfunction and/or biliary tract obstruction, decreasing or omitting copper and manganese supplements entirely may be necessary.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.


What might happen if I take too much Multitrace -4?

Symptoms of overdosage resulting from oral ingestion of Zinc Sulfate in large amounts have resulted in death. Symptoms included nausea, vomiting, dehydration, electrolyte imbalances, dizziness, abdominal pain, lethargy and incoordination. Single intravenous doses of 1 to 2 mg zinc/kg body weight have been given to adult leukemic patients without toxic manifestations. Normal plasma levels for Zinc vary from approximately 88 to 112 mcg/100 mL. Plasma levels sufficient to produce symptoms of toxic manifestations are not known. Calcium supplements may confer a protective effect against Zinc toxicity.

Symptoms of toxicity reported in literature include prostration, behavior change, diarrhea, progressive marasmus, hypotonia, photophobia and peripheral edema. D-penicillamine has been reported effective as an antidote.

MANGANESE

Symptoms of toxicity include nausea, vomiting, ulcers and gastrointestinal tract, renal and hepatic damage, and abnormalities of the central nervous system culminating in convulsions and coma. Trivalent Chromium administered intravenously to TPN patients has been shown to be nontoxic when given at dosage levels up to 250 mcg/day for two consecutive weeks.


How should I store and handle Multitrace -4?

Before reconstitutionDo not store lyophilized powder above 25°C (77°F).Reconstituted and infusion solutionsThe reconstituted solution, immediately diluted in 0.9% Sodium Chloride Injection may be stored at room temperature (25°C) and used within 6 hours or stored for 24 hours under refrigeration (5°C) and used within 4 hours after removal from refrigeration. Solutions of INVANZ should not be frozen.Before reconstitutionDo not store lyophilized powder above 25°C (77°F).Reconstituted and infusion solutionsThe reconstituted solution, immediately diluted in 0.9% Sodium Chloride Injection may be stored at room temperature (25°C) and used within 6 hours or stored for 24 hours under refrigeration (5°C) and used within 4 hours after removal from refrigeration. Solutions of INVANZ should not be frozen.Before reconstitutionDo not store lyophilized powder above 25°C (77°F).Reconstituted and infusion solutionsThe reconstituted solution, immediately diluted in 0.9% Sodium Chloride Injection may be stored at room temperature (25°C) and used within 6 hours or stored for 24 hours under refrigeration (5°C) and used within 4 hours after removal from refrigeration. Solutions of INVANZ should not be frozen.Before reconstitutionDo not store lyophilized powder above 25°C (77°F).Reconstituted and infusion solutionsThe reconstituted solution, immediately diluted in 0.9% Sodium Chloride Injection may be stored at room temperature (25°C) and used within 6 hours or stored for 24 hours under refrigeration (5°C) and used within 4 hours after removal from refrigeration. Solutions of INVANZ should not be frozen.MULTITRACE - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg.NDC 0517-7201-25                 1 mL Single Dose Vial                 Packaged in boxes of 25NDC 0517-7210-25                 10 mL Multiple Dose Vial*         Packaged in boxes of 25*Contains 0.9% Benzyl Alcohol as an antimicrobial preservative.AMERICANREGENT, INC.SHIRLEY, NY 11967IN7201Rev. 10/10MULTITRACE - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg.NDC 0517-7201-25                 1 mL Single Dose Vial                 Packaged in boxes of 25NDC 0517-7210-25                 10 mL Multiple Dose Vial*         Packaged in boxes of 25*Contains 0.9% Benzyl Alcohol as an antimicrobial preservative.AMERICANREGENT, INC.SHIRLEY, NY 11967IN7201Rev. 10/10MULTITRACE - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg.NDC 0517-7201-25                 1 mL Single Dose Vial                 Packaged in boxes of 25NDC 0517-7210-25                 10 mL Multiple Dose Vial*         Packaged in boxes of 25*Contains 0.9% Benzyl Alcohol as an antimicrobial preservative.AMERICANREGENT, INC.SHIRLEY, NY 11967IN7201Rev. 10/10MULTITRACE - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg.NDC 0517-7201-25                 1 mL Single Dose Vial                 Packaged in boxes of 25NDC 0517-7210-25                 10 mL Multiple Dose Vial*         Packaged in boxes of 25*Contains 0.9% Benzyl Alcohol as an antimicrobial preservative.AMERICANREGENT, INC.SHIRLEY, NY 11967IN7201Rev. 10/10MULTITRACE - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg.NDC 0517-7201-25                 1 mL Single Dose Vial                 Packaged in boxes of 25NDC 0517-7210-25                 10 mL Multiple Dose Vial*         Packaged in boxes of 25*Contains 0.9% Benzyl Alcohol as an antimicrobial preservative.AMERICANREGENT, INC.SHIRLEY, NY 11967IN7201Rev. 10/10MULTITRACE - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg.NDC 0517-7201-25                 1 mL Single Dose Vial                 Packaged in boxes of 25NDC 0517-7210-25                 10 mL Multiple Dose Vial*         Packaged in boxes of 25*Contains 0.9% Benzyl Alcohol as an antimicrobial preservative.AMERICANREGENT, INC.SHIRLEY, NY 11967IN7201Rev. 10/10MULTITRACE - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg.NDC 0517-7201-25                 1 mL Single Dose Vial                 Packaged in boxes of 25NDC 0517-7210-25                 10 mL Multiple Dose Vial*         Packaged in boxes of 25*Contains 0.9% Benzyl Alcohol as an antimicrobial preservative.AMERICANREGENT, INC.SHIRLEY, NY 11967IN7201Rev. 10/10MULTITRACE - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg.NDC 0517-7201-25                 1 mL Single Dose Vial                 Packaged in boxes of 25NDC 0517-7210-25                 10 mL Multiple Dose Vial*         Packaged in boxes of 25*Contains 0.9% Benzyl Alcohol as an antimicrobial preservative.AMERICANREGENT, INC.SHIRLEY, NY 11967IN7201Rev. 10/10MULTITRACE - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg.NDC 0517-7201-25                 1 mL Single Dose Vial                 Packaged in boxes of 25NDC 0517-7210-25                 10 mL Multiple Dose Vial*         Packaged in boxes of 25*Contains 0.9% Benzyl Alcohol as an antimicrobial preservative.AMERICANREGENT, INC.SHIRLEY, NY 11967IN7201Rev. 10/10MULTITRACE - 4 CONCENTRATE (TRACE ELEMENTS INJECTION 4, USP)Each mL provides: Zinc 5 mg, Copper 1 mg, Manganese 0.5 mg, and Chromium 10 mcg.NDC 0517-7201-25                 1 mL Single Dose Vial                 Packaged in boxes of 25NDC 0517-7210-25                 10 mL Multiple Dose Vial*         Packaged in boxes of 25*Contains 0.9% Benzyl Alcohol as an antimicrobial preservative.AMERICANREGENT, INC.SHIRLEY, NY 11967IN7201Rev. 10/10


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

ZINC

Providing zinc during TPN prevents development of the following deficiency symptoms: parakeratosis, hypogeusia, anorexia, dysosmia, geophagia, hypogonadism, growth retardation and hepatosplenomegaly. At plasma levels below 20 mcg zinc/100 mL, dermatitis followed by alopecia has been reported for TPN patients.

COPPER

Providing copper during TPN prevents development of the following deficiency symptoms: leukopenia, neutropenia, anemia, depressed ceruloplasmin levels, impaired transferrin formation and secondary iron deficiency.

MANGANESE

Providing manganese during TPN prevents development of the following deficiency symptoms: nausea and vomiting, weight loss, dermatitis, and changes in growth and color of hair.

CHROMIUM

Providing chromium during TPN prevents development of the following deficiency symptoms: impaired glucose tolerance, ataxia, peripheral neuropathy, and a confusional state similar to mild/moderate hepatic encephalopathy.

Non-Clinical Toxicology
MULTITRACE

- 4 CONCENTRATE

Copper and Manganese are eliminated via the bile. In patients with severe liver dysfunction and/or biliary tract obstruction, decreasing or omitting copper and manganese supplements entirely may be necessary.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

In one survey, 2.3% of patients taking labetalol hydrochloride in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol hydrochloride alone. The contribution of each of the treatments to this adverse reaction is unknown, but the possibility of a drug interaction cannot be excluded.

Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal anti-asthmatic dose of beta-agonist bronchodilator drugs may be required.

Cimetidine has been shown to increase the bioavailability of labetalol hydrochloride. Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol hydrochloride, special care should be used in establishing the dose required for blood pressure control in such patients.

Synergism has been shown between halothane anesthesia and intravenously administered labetalol hydrochloride. During controlled hypotensive anesthesia using labetalol hydrochloride in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol hydrochloride.

Labetalol hydrochloride blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect. If labetalol hydrochloride is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.

Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.

Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Before administering in TPN solutions, the physician must assess the metabolic requirements for trace elements and disease state of the patient. Frequent determinations of serum levels of the various trace elements are suggested as a guideline for adjusting the dosage or completely omitting the solution. is eliminated via the intestine and kidneys. The possibility of retention should be considered in patients with malfunctioning excretory routes. and are eliminated via the bile, therefore, the possibility of the retention of these elements should be considered in patients with biliary obstruction. Ancillary routes of excretion, however, include pancreatic juice, or reabsorption into the lumen of duodenum, jejunum, or ileum.

In assessing the contribution of supplements to maintenance of normal glucose homeostasis, consideration should be given to the possibility that the patient may be diabetic, in which case oral or intravenous antidiabetic medication may be indicated.

The amounts of AND in the solution are very small and toxicity symptoms due to these trace elements at suggested dosage levels are considered unlikely to occur.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).